← Leaderboards
Lily Yang
Emory University
$15,527,458
Attributed
$24,754,090
Total exposure
15
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$24,754,090 · 15
By mechanism
R01$16,838,199 · 9
U01$5,159,268 · 2
R44$1,776,357 · 1
R29$425,478 · 1
R41$330,363 · 1
R43$224,425 · 1
Top collaborators
- Hui Mao35 shared
- Y Andrew Wang6 shared
- Lei Zhu5 shared
- Huabei Jiang4 shared
- H Trent Spencer2 shared
- Lingxun Duan1 shared
Most similar at Emory University
Same institution · by research overlap
- Hui Mao$16,442,940
- Adam I Marcus$15,360,223
- Yuesong Hu$278,044
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorChemotherapyUrokinase Plasminogen Activator ReceptorNeoplastic CellNanoparticleTissuesBiodistributionTargeted DeliveryPharmaceutical PreparationsDrug Delivery SystemsResponseMagnetismMagnetic Resonance ImagingMalignant Neoplasm Of PancreasResearch Project GrantsDrug ResistanceReceptorMonitorDrug KineticsTherapeutic EffectLigandsCancer PatientStromal CellsTreatment Response
Grant awards (73)
Stroma penetrating and immune modulating nanoparticles for image-guided therapy of pancreatic cancer$472,215
R01 · FY2025 · CA · contact PI
Development of multifunctional drug and immune modulator delivery nanoparticles for the treatment of cancer patients with comorbid atherosclerosis$366,421
R01 · FY2025 · CA · contact PI
Stroma penetrating and immune modulating nanoparticles for image-guided therapy of pancreatic cancer$72,891
R01 · FY2025 · CA · contact PI
Stroma penetrating and immune modulating nanoparticles for image-guided therapy of pancreatic cancer$448,604
R01 · FY2024 · CA · contact PI
Development of multifunctional drug and immune modulator delivery nanoparticles for the treatment of cancer patients with comorbid atherosclerosis$149,521
R01 · FY2024 · CA · contact PI
Stroma penetrating and immune modulating nanoparticles for image-guided therapy of pancreatic cancer$69,246
R01 · FY2024 · CA · contact PI
Stroma penetrating and immune modulating nanoparticles for image-guided therapy of pancreatic cancer$69,246
R01 · FY2024 · CA · contact PI
Translational Development of a Targeted and Stroma-penetrating Nanoparticle Drug for Pancreatic Cancer Therapy$841,919
R44 · FY2023 · CA
Development of multifunctional drug and immune modulator delivery nanoparticles for the treatment of cancer patients with comorbid atherosclerosis$532,237
R01 · FY2023 · CA · contact PI
Stroma penetrating and immune modulating nanoparticles for image-guided therapy of pancreatic cancer$462,770
R01 · FY2023 · CA · contact PI
Stroma penetrating and immune modulating nanoparticles for image-guided therapy of pancreatic cancer$28,146
R01 · FY2023 · CA · contact PI
Translational Development of a Targeted and Stroma-penetrating Nanoparticle Drug for Pancreatic Cancer Therapy$934,438
R44 · FY2022 · CA
Development of multifunctional drug and immune modulator delivery nanoparticles for the treatment of cancer patients with comorbid atherosclerosis$532,237
R01 · FY2022 · CA · contact PI
Stroma penetrating and immune modulating nanoparticles for image-guided therapy of pancreatic cancer$462,770
R01 · FY2022 · CA · contact PI
Development of multifunctional drug and immune modulator delivery nanoparticles for the treatment of cancer patients with comorbid atherosclerosis$542,085
R01 · FY2021 · CA · contact PI
Stroma penetrating and immune modulating nanoparticles for image-guided therapy of pancreatic cancer$486,085
R01 · FY2021 · CA · contact PI
Targeted therapy of peritoneal carcinomatosis using theranostic nanoparticles$411,268
R01 · FY2020 · CA · contact PI
Tumor Stroma Breaking System for Efficient Delivery of Therapeutic Agents$224,860
R41 · FY2020 · CA · contact PI
Tumor Stroma Breaking System for Efficient Delivery of Therapeutic Agents$105,503
R41 · FY2020 · CA · contact PI
A multimodal imaging system and targeted nanoprobes for image-guided treatment of breast cancer$613,368
R01 · FY2019 · EB
Stroma Breaking Theranostic Nanoparticle for Targeted Pancreatic Cancer Therapy$469,682
U01 · FY2019 · CA · contact PI
Targeted therapy of peritoneal carcinomatosis using theranostic nanoparticles$398,930
R01 · FY2019 · CA · contact PI
Targeted therapy of peritoneal carcinomatosis using theranostic nanoparticles$369,115
R01 · FY2019 · CA · contact PI
Translational Development of a Targeted and Stroma-breaking Nanoparticle Drug for Pancreatic Cancer Therapy$224,425
R43 · FY2019 · CA
A multimodal imaging system and targeted nanoprobes for image-guided treatment of breast cancer$622,134
R01 · FY2018 · EB
Stroma Breaking Theranostic Nanoparticle for Targeted Pancreatic Cancer Therapy$511,061
U01 · FY2018 · CA · contact PI
Targeted therapy of peritoneal carcinomatosis using theranostic nanoparticles$411,268
R01 · FY2018 · CA · contact PI
A multimodal imaging system and targeted nanoprobes for image-guided treatment of breast cancer$605,704
R01 · FY2017 · EB
Stroma Breaking Theranostic Nanoparticle for Targeted Pancreatic Cancer Therapy$595,122
U01 · FY2017 · CA · contact PI
Targeted therapy of peritoneal carcinomatosis using theranostic nanoparticles$411,268
R01 · FY2017 · CA · contact PI
Stroma Breaking Theranostic Nanoparticle for Targeted Pancreatic Cancer Therapy$56,018
U01 · FY2017 · CA · contact PI
A Multimodal Imaging System and Targeted Nanoprobes for Image-Guided Treatment of Breast Cancer$752,876
R01 · FY2016 · EB
Stroma Breaking Theranostic Nanoparticle for Targeted Pancreatic Cancer Therapy$729,411
U01 · FY2016 · CA · contact PI
Targeted therapy of peritoneal carcinomatosis using theranostic nanoparticles$425,268
R01 · FY2016 · CA · contact PI
Stroma Breaking Theranostic Nanoparticle for Targeted Pancreatic Cancer Therapy$56,018
U01 · FY2016 · CA · contact PI
Stroma Breaking Theranostic Nanoparticle for Targeted Pancreatic Cancer Therapy$574,292
U01 · FY2015 · CA · contact PI
MRI Capable Receptor Targeted Drug Delivery for Pancreatic Cancer$390,270
R01 · FY2015 · CA
Mechanisms of Herceptin resistance$321,853
R01 · FY2015 · CA · contact PI
Targeted Therapy of Triple Negative Breast Cancer Using Theranostic Nanoparticles$320,906
R01 · FY2015 · CA · contact PI
Mechanisms of Herceptin resistance$55,344
R01 · FY2015 · CA · contact PI
Mechanisms of Herceptin resistance$54,450
R01 · FY2015 · CA · contact PI
MRI Capable Receptor Targeted Drug Delivery for Pancreatic Cancer$15,751
R01 · FY2015 · CA
Theranostic Nano particles for Targeted Treatment of Pancreatic Cancer$395,425
U01 · FY2014 · CA · contact PI
MRI Capable Receptor Targeted Drug Delivery for Pancreatic Cancer$379,123
R01 · FY2014 · CA
Targeted Therapy of Triple Negative Breast Cancer Using Theranostic Nanoparticles$312,222
R01 · FY2014 · CA · contact PI
MRI Capable Receptor Targeted Drug Delivery for Pancreatic Cancer$100,750
R01 · FY2014 · CA
Targeted Therapy of Triple Negative Breast Cancer Using Theranostic Nanoparticles$56,011
R01 · FY2014 · CA · contact PI
Theranostic Nano particles for Targeted Treatment of Pancreatic Cancer$471,193
U01 · FY2013 · CA · contact PI
MRI Capable Receptor Targeted Drug Delivery for Pancreatic Cancer$367,956
R01 · FY2013 · CA
Targeted Therapy of Triple Negative Breast Cancer Using Theranostic Nanoparticles$308,741
R01 · FY2013 · CA · contact PI
MRI Capable Receptor Targeted Drug Delivery for Pancreatic Cancer$88,115
R01 · FY2013 · CA
Targeted Therapy of Triple Negative Breast Cancer Using Theranostic Nanoparticles$57,744
R01 · FY2013 · CA · contact PI
MRI Capable Receptor Targeted Drug Delivery for Pancreatic Cancer$392,047
R01 · FY2012 · CA
Theranostic Nano particles for Targeted Treatment of Pancreatic Cancer$391,244
U01 · FY2012 · CA · contact PI
Targeted Therapy of Triple Negative Breast Cancer Using Theranostic Nanoparticles$332,397
R01 · FY2012 · CA · contact PI
Targeted Nanoprobes For Intraoperative optical Imaging of Breast Cancer Margins$309,239
R01 · FY2012 · CA · contact PI
Theranostic Nano particles for Targeted Treatment of Pancreatic Cancer$438,285
U01 · FY2011 · CA · contact PI
MRI Capable Receptor Targeted Drug Delivery for Pancreatic Cancer$405,027
R01 · FY2011 · CA
Targeted Therapy of Triple Negative Breast Cancer Using Theranostic Nanoparticles$343,902
R01 · FY2011 · CA · contact PI
Targeted Nanoprobes For Intraoperative optical Imaging of Breast Cancer Margins$309,239
R01 · FY2011 · CA · contact PI
Theranostic Nano particles for Targeted Treatment of Pancreatic Cancer$471,517
U01 · FY2010 · CA · contact PI
Targeted Nanoprobes For Intraoperative optical Imaging of Breast Cancer Margins$318,803
R01 · FY2010 · CA · contact PI
Targeted Nanoprobes For Intraoperative optical Imaging of Breast Cancer Margins$318,803
R01 · FY2009 · CA · contact PI
Targeted Nanoprobes For Intraoperative optical Imaging of Breast Cancer Margins$329,247
R01 · FY2008 · CA · contact PI
IAPs As Novel Targets for Cancer Therapy$239,605
R01 · FY2007 · CA · contact PI
IAPs As Novel Targets for Cancer Therapy$246,761
R01 · FY2006 · CA · contact PI
IAPs As Novel Targets for Cancer Therapy$252,700
R01 · FY2005 · CA
IAPs As Novel Targets for Cancer Therapy$250,230
R01 · FY2004 · CA
IAPs As Novel Targets for Cancer Therapy$245,290
R01 · FY2003 · CA
DEATH SIGNALING IN HSV-TK GENE MODIFIED TUMOR CELLS$110,797
R29 · FY2003 · CA
DEATH SIGNALING IN HSV-TK GENE MODIFIED TUMOR CELLS$107,659
R29 · FY2002 · CA
DEATH SIGNALING IN HSV-TK GENE MODIFIED TUMOR CELLS$104,670
R29 · FY2001 · CA
DEATH SIGNALING IN HSV-TK GENE MODIFIED TUMOR CELLS$102,352
R29 · FY2000 · CA